Christine Desbiens
Chercheuse associée
Axe Oncologie
Publications
Voir tout-
article Lemieux J, Côté I, Lemay M, Lauzier S, Després P, Desbiens C, Doyle C, Poirier B, Baghdadli A, Di Schiavi Trotta L, Nabi H
Development and Evaluation of a Web-Based App for Adverse Effect Management in Breast Cancer Patients Treated with Oral Targeted Therapy or Chemotherapy: Findings from a Pilot St…
Curr Oncol 33 (5), 2026.
-
article Weintritt DC, Lesnikoski BA, Goecke ME, Desbiens C, Wilton AK, Dipasquale AA, Gunia SR
A single arm, prospective, open label, multicenter study assessing the safety and effectiveness of SPY AGENT GREEN and SPY fluorescence imaging systems in the visualization of ly…
SURGICAL ONCOLOGY INSIGHT 2 (4), 2025.
-
article Haroun O, Lapointe J, Guérard R, Bergeron AS, Raîche C, Chiquette J, Bouchard K, Pomey MP, Hébert J, Olivier Chevrier G, Lachapelle P, Omeranovic A, Côté M, Boily L, Brisson C, Gekas J, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Boisvert K, Brousseau C, Castonguay L, Gosselin I, Renaud MC, Ruiz Mangas MG, Paquet-Beaupré A, Bélanger ME, Racine MM, Roy MC, Blanchette S, Faucher V, Leblanc J, Dubeau ME, Cavaillé M, Plante M, Desbiens C, Beaumont M, Simard J, Dorval M, Nabi H
Genetic counseling services for hereditary breast and ovarian cancer: patients experience and satisfaction with different service models
Eur J Hum Genet 2026.
Projets
- Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, du 2023-04-01 au 2026-07-31
- COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib , du 2024-03-12 au 2029-12-25
- Comparative effectiveness of opioid versus opioid-free post-discharge analgesia after outpatient breast surgery: A randomized controlled trial, du 2024-07-23 au 2029-12-25
- LAVIE: Living Labs for Oncology Supportive Care and Rehabilitation, du 2025-02-04 au 2027-02-04
- Vers une plateforme intégrée de soins et de recherche en oncologie (MediFirst GENETICS), du 2026-01-19 au 2027-03-31
- OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy , du 2024-04-26 au 2025-02-28
- From survival to quality of life: developing and implementing priorities- and values-based personalized supportive and rehabilitation care pathways with and for people with advanced breast cancer, du 2024-07-15 au 2024-10-15